Key Highlights
- AbbVie commits $1.4 billion toward constructing a 185-acre pharmaceutical manufacturing facility in Durham, North Carolina
- Represents the pharmaceutical giant’s most significant capital expenditure for a single location in company history
- Facility will manufacture sterile injectable treatments targeting immunology, neuroscience, and oncology conditions
- Expected to generate 734 full-time positions throughout a four-year period, alongside more than 2,000 construction-related jobs
- Development phase begins in 2026, with full operational status anticipated by late 2028
Pharmaceutical leader AbbVie revealed plans Wednesday to develop a $1.4 billion manufacturing complex in Durham, North Carolina — representing the company’s most substantial investment in a single facility to date.
The sprawling 185-acre development will be strategically positioned adjacent to Research Triangle Park, functioning as AbbVie’s premier U.S. hub for small volume parenteral (SVP) production. The facility will specialize in sterile injectable medications — including vials, syringes, and prefilled cartridge systems — designed for treating diseases spanning immunology, neuroscience, and oncology therapeutic areas.
This marks AbbVie’s inaugural substantial presence within North Carolina’s pharmaceutical landscape.
Ground-breaking activities are scheduled to commence later in 2026, with the entire complex projected to reach full operational capacity before 2028 concludes. Initial construction phases encompass manufacturing facilities, research laboratories, warehousing infrastructure, administrative offices, and employee wellness amenities.
The pharmaceutical company intends to recruit 734 permanent staff members throughout a four-year hiring timeline — including engineers, research scientists, manufacturing specialists, and laboratory technicians. The construction phase will simultaneously generate employment opportunities for over 2,000 workers during the development period.
Chief Executive Officer Robert A. Michael stated the commitment “reinforces our capacity to facilitate future therapeutic innovations while simultaneously establishing new employment opportunities and fostering an enduring collaboration with Durham and North Carolina.”
Component of an Expansive $100 Billion Domestic Investment Strategy
The Durham manufacturing complex represents a single element within a significantly larger strategic initiative. AbbVie has committed to allocating approximately $100 billion toward U.S.-based research, development, and manufacturing operations throughout the coming decade.
Within just the previous twelve months, the pharmaceutical corporation has dedicated more than $2.2 billion to domestic manufacturing initiatives spanning North Carolina, Illinois, Arizona, and Massachusetts.
This past February, AbbVie disclosed a $380 million investment to construct two active pharmaceutical ingredient production facilities at its North Chicago, Illinois headquarters, concentrating on neuroscience and obesity therapeutic compounds.
The Durham location builds upon this expansion trajectory.
Strategic Selection of North Carolina
AbbVie selected the Research Triangle Park region based on its highly qualified local talent pool and substantial capacity for future growth.
North Carolina Governor Josh Stein embraced the announcement, characterizing the state as “the leading destination for biopharmaceutical enterprises to establish operations.”
Upon completion, the manufacturing complex will distribute pharmaceutical products to both domestic and global markets, serving as a pivotal distribution center for AbbVie’s injectable medication production throughout the United States.
AbbVie presently maintains a workforce of approximately 29,000 employees throughout the United States, including over 6,000 staff members at its domestic production facilities. Following this announcement, the company’s aggregate U.S. employment expansion commitment during the past year now surpasses 1,300 newly created positions distributed across four states.
The complex will additionally incorporate artificial intelligence and cutting-edge manufacturing technologies throughout its operational framework — a capability AbbVie emphasized in its official statement.
The initiative signifies AbbVie’s initial expansion into North Carolina as a manufacturing jurisdiction, with company representatives noting the location has been architecturally designed to accommodate future pipeline development requirements.
